- Conference Call Today at 4:30 p.m. Eastern Time -
SAN FRANCISCO, Nov. 10 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the quarter ended September 30, 2008.
"The third quarter represented another quarter of significant
achievement and progress and was capped with the signing of our partnering
agreement with Pfizer for Dimebon. This collaboration not only gives us
access to a world-class partner capable of maximizing global
commercialization, but also provides significant funding allowing us to
invest in all of our clinical programs and actively pursue other drug
candidates," said David Hung, M.D., president and chief executive officer
of Medivation. "We are working with Pfizer on an extensive program to
support a broad label for Dimebon in Alzheimer's disease beyond our
original plan to pursue the treatment of mild-to-moderate Alzheimer's, and
to achieve comprehensive and expeditious regulatory submissions and market
acceptance. Accordingly, together we intend to expand development of
Dimebon to include new Phase 3 trials in addition to the CONNECTION study.
We expect to begin the new trials in 2009 and to file a New Drug
Application (NDA) for a broader Alzheimer's disease label in 2011."
Dimebon: Drug candidate to treat Alzheimer's and Huntington's diseases
-- Entered into an agreement with Pfizer Inc. to jointly develop and
commercialize Dimebon for the treatment of Alzheimer's and Huntington's
diseases. Under the terms of the agreement, Medivation has received an
up-front cash payment of $225 million and is eligible to receive
payments of up to $500 mill
|SOURCE Medivation, Inc.|
Copyright©2008 PR Newswire.
All rights reserved